Secondary Logo

Journal Logo

Editorial introductions

Current Opinion in Organ Transplantation: August 2007 - Volume 12 - Issue 4 - p viii–ix
doi: 10.1097/01.mot.0000280473.55728.20
Editorial introductions
Free

Current Opinion in Organ Transplantation was launched in 1996. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of organ transplantation is divided into 18 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

Back to Top | Article Outline

Section Editors

Haval Shirwan

Figure 1

Figure 1

Dr Shirwan is currently a University Scholar, Professor of Microbiology and Immunology and the Director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutic, University of Louisville, KY, USA. He obtained his BSc from Hacettepe University in Ankara, Turkey, and his MSc and PhD degrees from the University of California in Santa Barbara, followed by a postdoctoral position at the California Institute of Technology in Pasadena, CA. He previously held the positions of Associate Director at the Transplantation Biology Research Laboratory, Cedars-Sinai Medical Center and Transplantation Biology Research Laboratory, St. Vincent Medical Center, as well as being the Associate Professor of Surgery at the Allegheny University of Health Sciences, Philadelphia, USA.

Dr Shirwan's research has focused on various aspects of transplantation immunology, including the study of T cell responses to allogeneic and xenogeneic antigens, contribution of direct and indirect allo/xenoantigen recognition pathways to graft rejection, TCR and Ab repertoires utilized in response to allo/xenoantigens, and modulation of T cell responses to induce transplantation tolerance. In recent years, he focused on translational research and pioneered the ProtEx technology as a safe, efficient, and practical alternative to DNA-based immune gene therapy to display exogenous proteins with well-defined immune functions on the surface of cells, tissues, and organs for immunomodulation with application to transplantation, autoimmunity, and vaccinology. The ProtEx technology is licensed from the University of Louisville by ApoImmune, Inc., for commercialization purposes. Dr Shirwan is the scientific founder and Chief Scientific Officer of the Company. He has published 69 peer-reviewed articles, 8 review articles/book chapters, and 50 abstracts. He is presently a member of NIH and American Heart Study Sections and has served on study sections for various profit and non-profit funding agencies. Dr Shirwan is a member of various national and international societies and also served on the editorial boards of various journals. His various awards include North Atlantic Treaty Organization PhD Scholarship, American Society of Transplant Physicians-Ortho Award, Cedars-Sinai Medical Center Young Investigator Award, Business First, Partners in Health Care Award, and First Place, Faculty Category for Innovation in Biotechnology, Research!Louisville, Louisville, KY, USA.

Back to Top | Article Outline

Ron Shapiro

Figure 2

Figure 2

Dr Ron Shapiro is Professor of Surgery at the University of Pittsburgh School of Medicine and Director of Kidney, Pancreas, & Islet Transplantation at the Thomas E. Starzl Transplantation Institute in Pittsburgh, Pennsylvania. He graduated from medical school in 1980 from Stanford University, and completed a general surgical residency at the Mt. Sinai Hospital in New York in 1986, and a transplant fellowship at the University of Pittsburgh in 1988.

The focus of his research has been generally within the fields of clinical renal and pancreatic transplantation, and more specifically, with the development and optimization of immunosuppressive protocols. Dr Shapiro has conducted a number of randomized clinical trials to demonstrate the efficacy of tacrolimus-based immunosuppression, and has helped develop the agent for use in clinical renal and pancreatic transplantation. More recently, he has focused on strategies to minimize immunosuppression after transplantation. Additional interests include analysis of adverse events related to immunosuppression, including post-transplant diabetes mellitus and viral infections, including cytomegalovirus, Epstein-Barr virus, and BK virus.

Dr Shapiro serves on the editorial board of the American Journal of Transplantation, Transplantation, Clinical Transplantation, and Pediatric Transplantation. Dr Shapiro is member of several professional societies including the American Society of Transplant Surgeons, The Transplantation Society, Association for Academic Surgery, American Society of Transplantation, the International Pancreas and Islet Transplant Association, The Society of University Surgeons, American Surgical Association, and International Pediatric Transplant Association. His most recent appointment is serving as President of the North American Paired Donor Network. Dr Shapiro has published 300 refereed articles, 4 books, 50 book chapters, over 80 internet publications, and has given over 400 lectures.

Back to Top | Article Outline

Thalachallour Mohanakumar

Figure 3

Figure 3

Thalachallour Mohanakumar, PhD is the Jacqueline G. and William Maritz Professor of Surgery at Washington University School of Medicine in St. Louis, Missouri. He is a Professor of Surgery, Pathology and Immunology, and the Director of the Clinical Histocompatibility and Immunogenetics Laboratory at Barnes-Jewish Hospital, Washington University School of Medicine. Dr Mohanakumar is also the Director of the Islet Isolation Facility at Washington University School of Medicine. Dr Mohanakumar, received his PhD in Microbiology and Immunology in 1974 from Duke University, Durham, North Carolina. He is currently funded for his research in Transplantation and Tumor Immunology by the National Institutes of Health and the Juvenile Diabetes Research Foundation.

Dr Mohanakumar has been a member of several National Institutes of Health Peer review groups for research funding and was the Chairman of the Transplantation Biology and Immunology Subcommittee. He is a member of the International Xenotransplantation Society, International Society Heart Lung Transplantation, Transplantation Society, American Society of Transplantation, American Society of Histocompatibility and Immunogenetics, and the American Society for Cancer Research. He is also a consultant for review groups of the Juvenile Diabetes Foundation and the US Department of Defense for Breast Cancer Research.

Dr Mohanakumar is currently serving as a member on the Editorial Board of scientific journals including Transplantation, Journal of Immunology, Human Immunology, and Transplantation Immunology. He was awarded the 2001 Fujisawa Basic Science Award by the American Society of Transplantation and a 2003 Distinguished Scientist Award from the American Society of Histocompatibility and Immunogenetics.

Back to Top | Article Outline

Ankit Bharat

Figure 4

Figure 4

Dr Bharat is a resident in general surgery at Washington University school of Medicine/Barnes-Jewish Hospital, St Louis. He obtained his medical training at Christian Medical College, Vellore, India. He did his post-doctoral fellowship in Dr T Mohanakumar's lab at Washington University, St Louis. Dr Bharat has a strong interest in transplant and tumor immunobiology. His work on the role of cellular tolerance in lung transplantation and early post-transplant injuries in chronic allograft rejection has been recognized for excellence by different transplant committees. He has presented his work in both national and international meetings and has given invited to give lectures internationally. He aspires to pursue his career as a surgeon-scientist.

© 2007 Lippincott Williams & Wilkins, Inc.